Quick Dispatch:
Your tirzepatide diabetes trial At a glance factsheet: Tirzepatide for management of type 2 diabetes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide diabetes trial At a glance factsheet: Tirzepatide for management of type 2 diabetes ships.
Need Help?
Questions about tirzepatide diabetes trial At a glance factsheet: Tirzepatide for management of type 2 diabetes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide diabetes trial At a glance factsheet: Tirzepatide for management of type 2 diabetes in your area.
💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What
22.02
Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study
29.42
Tirzepatide enhances weight loss with sustained treatment but discontinuation leads to weight regain
26.24
Semaglutide vs. Tirzepatide for Obesity
27.36
Tirzepatide Shows Superior Weight Loss Over Semaglutide in Phase 3 Trial
25.99
Tirzepatide cuts risk of diabetes by 94% in adults with prediabetes and obesity or overweight, drugmaker says
26.77
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
22.58
/assets/images/provider/photos/2803587.png)
